𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant α-interferon for chronic non-A, non-B hepatitis

✍ Scribed by Masao Omata; Yoshimi Ito; Osamu Yokosuka; Fumio Imazeki; Masami Tagawa; Susumu Takano; Kazuhiko Hosoda; Minoru Tada; Masao Ohto; Kazuto Ito; Kunio Okuda

Book ID
112512755
Publisher
Springer US
Year
1991
Tongue
English
Weight
527 KB
Volume
36
Category
Article
ISSN
0163-2116

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant human α-interferon in patien
Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France
✍ Patrick Marcellin; Nathalie Boyer; Emile Giostra; Claude Degott; Anne Marie Cour 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB

We have conducted a multicenter randomized controlled trial comparing two doses of recombinant human a-interferon for efficacy in 60 patients with chronic non-A, non-B hepatitis. The source of infection appeared to be transfusion in 30 patients, intravenous drug abuse in 16 patients and was unknown

Interferon-α and zidovudine combination
Interferon-α and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo-controlled trial
✍ Harry L. A. Janssen; Luuk Berk; Rudolf A. Heijtink; Fiebo J. W. Ten Kate; Solko 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 630 KB

Interferon-a therapy leads to HBeAg seroconversion in only one third of patients with chronic hepatitis B. In an attempt to increase the seroconversion rate, we investigated the combination of interferon-a and zidovudine in a subset of patients with presumably low response rates for interferon-a mon

High doses of recombinant α-interferon o
High doses of recombinant α-interferon or γ-interferon for chronic hepatitis C: A randomized, controlled trial
✍ Federico Sáez-royuela; Juan Carlos Porres; Alberto Moreno; Inmaculada Castillo; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB

Chronic hepatitis C is often a progressive liver disease for which there is no satisfactory treatment. We studied the efficacy of recombinant a-interferon or y-interferon in the treatment of this disease in comparison with a control group. Thirty patients were randomly assigned to three groups. Ten